Working… Menu

Phase 3 Extension Study of Dexpramipexole in ALS (ENVISION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01622088
Recruitment Status : Terminated (The Initial Phase 3 Study (NCTO1281189) did not meet its primary efficacy endpoint.)
First Posted : June 18, 2012
Last Update Posted : December 15, 2017
Information provided by (Responsible Party):
Knopp Biosciences

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : February 2013
Actual Study Completion Date : February 2013
Certification/Extension First Submitted : November 24, 2014